Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Theranostics
Coussy, Florence F; Lavigne, Marion M; de Koning, Leanne L; Botty, Rania El RE; Nemati, Fariba F; Naguez, Adnan A; Bataillon, Guillaume G; Ouine, Berengère B; Dahmani, Ahmed A; Montaudon, Elodie E; Painsec, Pierre P; Chateau-Joubert, Sophie S; Laetitia, Fuhrmann F; Larcher, Thibaut T; Vacher, Sophie S; Chemlali, Walid W; Briaux, Adrien A; Melaabi, Samia S; Salomon, Anne Vincent AV; Guinebretiere, Jean Marc JM; Bieche, Ivan I; Marangoni, Elisabetta E
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.
Genome Research
Brammeld, Jonathan S JS; Petljak, Mia M; Martincorena, Inigo I; Williams, Steven P SP; Alonso, Luz Garcia LG; Dalmases, Alba A; Bellosillo, Beatriz B; Robles-Espinoza, Carla Daniela CD; Price, Stacey S; Barthorpe, Syd S; Tarpey, Patrick P; Alifrangis, Constantine C; Bignell, Graham G; Vidal, Joana J; Young, Jamie J; Stebbings, Lucy L; Beal, Kathryn K; Stratton, Michael R MR; Saez-Rodriguez, Julio J; Garnett, Mathew M; Montagut, Clara C; Iorio, Francesco F; McDermott, Ultan U
Publication Date: 2017-04
Variant appearance in text: PIK3CA: 3143A>T; H1048L